AI Summary & Key Takeaways
AI InsightPathology reporting time, chemotherapy administration time, preoperative preparation time and overall time from diagnosis to treatment were similar (p=0.305, p=0.171, p=0.104, p=0.061, respectively).
📌 3 Key Takeaways
Abstract
Aim: In this study, we investigated the effect of pandemic on the diagnosis-treatment process in breast cancer patients receiving neoadjuvant chemotherapy. Materials and Methods: The clinicopathological characteristics of the total patients who received neoadjuvant chemotherapy for one year during the Coronavirus disease-2019 (COVID-19) pandemic period and one year before the pandemic were compared. A total of 92 patients were analyzed retrospectively. Results: The clinicopathological features in the pandemic and prepandemic periods were found to be similar. While the number of patients was 26 (28.3%) during the pandemic period, it was 66 (71.7%) in the prepandemic period. Pathology reporting time, chemotherapy administration time, preoperative preparation time and overall time from diagnosis to treatment were similar (p=0.305, p=0.171, p=0.104, p=0.061, respectively). Magnetic resonance reporting time was shorter during the pandemic period (p=0.005). Conclusion: The diagnosis and treatment times of breast cancer in patients receiving neoadjuvant chemotherapy in the pandemic period are similar to those in the pre-pandemic period. Nevertheless, decision should be made on a patient-specific basis considering COVID-19 infection risk.
Özet
Amaç: Bu çalışmamızda neoadjuvan kemoterapi alan meme kanseri hastalarında pandeminin tanı-tedavi sürecine etkisini araştırdık. Gereç ve Yöntem: Koronavirüs hastalığı-2019 (COVID-19) pandemisi dönemindeki bir yıl ile pandemi öncesindeki 1 yılda neoadjuvan kemoterapi alan hastaların klinikopatolojik özellikleri ile tanıdan operasyona kadar olan aşamaların süreleri karşılaştırıldı. Toplam 92 hasta retrospektif olarak analiz edildi. Bulgular: Pandemi ve pandemi öncesi (prepandemik) dönemdeki hastaların klinikopatolojik özellikleri benzer bulundu. Pandemi dönemindeki hasta sayısı 26 (%28,3) iken pandemi öncesi dönemde 66 (%71,7) idi. Tanı-tedavi sürelerinden patoloji raporlanma süresi, kemoterapi uygulanma süresi ve preoperatif hazırlık dönemi ve total süre iki dönem arasında benzerdi (sırasıyla; p=0,305, p=0,171, p=0,104, p=0,061). Manyetik rezonans raporlanma süresi pandemi döneminde daha kısa saptandı (p=0,005). Sonuç: Neoadjuvan kemoterapi alan hastalarda meme kanserinin tanı ve tedavi süreleri pandemi döneminde, pandemi öncesi dönemle benzerdir. Yine de COVID-19 enfeksiyon riski düşünülerek hasta özelinde karar verilmelidir.